Caribou Biosciences Q2 net loss narrows
Caribou Biosciences Q2 net loss narrows
Overview
US genome-editing biopharma's Q2 licensing revenue fell yr/yr, net loss narrowed
Company reduced R&D and G&A expenses due to workforce cuts and pipeline prioritization
Cash position expected to fund operations through end of 2027, including key clinical trials
Outlook
Company expects to report initial CB-011 dose expansion data in H2 2026
Caribou says cash and equivalents sufficient to fund operations through end of 2027
Company is exploring options to fully fund planned ANTLER-3 pivotal phase 3 trial
Result Drivers
CLINICAL DATA PROGRESS - Co said new phase 1 data for vispa-cel and CB-011 showed durable, deep responses in lymphoma and myeloma patients, supporting continued clinical development
Company press release: ID:nGNX76qB7R
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Basic Share |
| $0.24 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Caribou Biosciences, Inc. is $10.50, about 517.6% above its August 12 closing price of $1.70
Reuters Recommended Reads
Aug 13 - Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Aug 13 - Instil Bio Q2 net loss narrows on lower R&D spending, restructuring charges
Aug 11 - Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)